198 related articles for article (PubMed ID: 29349515)
1. Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity.
Ertugrul G; Keles D; Oktay G; Aktan S
Arch Dermatol Res; 2018 Mar; 310(2):173-179. PubMed ID: 29349515
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
4. Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function.
Adamidis KN; Kopaka ME; Petraki C; Charitaki E; Apostolou T; Christodoulidou C; Nikolopoulou N; Giatromanolaki A; Vargemesis V; Passadakis P
Ren Fail; 2019 Nov; 41(1):229-237. PubMed ID: 30973283
[TBL] [Abstract][Full Text] [Related]
5. The expression of human corneal MMP-2, MMP-9, proMMP-13 and TIMP-1 in bullous keratopathy and keratoconus.
Predović J; Balog T; Marotti T; Gabrić N; Bohac M; Romac I; Dekaris I
Coll Antropol; 2008 Oct; 32 Suppl 2():15-9. PubMed ID: 19138000
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Niimi Y; Pawankar R; Kawana S
Int Arch Allergy Immunol; 2006; 139(2):104-13. PubMed ID: 16374020
[TBL] [Abstract][Full Text] [Related]
8. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
9. [The expression of matrix metalloproteinases and their tissue inhibitors in pleomorphic adenoma].
Chen Y; Tian K; Geng N; Yang MZ; Zhang WP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan; 40(1):58-61. PubMed ID: 15774155
[TBL] [Abstract][Full Text] [Related]
10. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
Chua PK; Melish ME; Yu Q; Yanagihara R; Yamamoto KS; Nerurkar VR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):308-14. PubMed ID: 12626459
[TBL] [Abstract][Full Text] [Related]
13. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency.
Saito S; Trovato MJ; You R; Lal BK; Fasehun F; Padberg FT; Hobson RW; Durán WN; Pappas PJ
J Vasc Surg; 2001 Nov; 34(5):930-8. PubMed ID: 11700497
[TBL] [Abstract][Full Text] [Related]
14. Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade.
Symeonidis C; Papakonstantinou E; Androudi S; Georgalas I; Rotsos T; Karakiulakis G; Diza E; Dimitrakos SA
Cytokine; 2014 Jun; 67(2):71-6. PubMed ID: 24725542
[TBL] [Abstract][Full Text] [Related]
15. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
17. Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers.
Raitio A; Tuomas H; Kokkonen N; Salo T; Sorsa T; Hanemaaijer R; Oikarinen A
Arch Dermatol Res; 2005 Dec; 297(6):242-8. PubMed ID: 16215764
[TBL] [Abstract][Full Text] [Related]
18. Effects of Plasmodium falciparum-infected erythrocytes on matrix metalloproteinase-9 regulation in human microvascular endothelial cells.
D'Alessandro S; Basilico N; Prato M
Asian Pac J Trop Med; 2013 Mar; 6(3):195-9. PubMed ID: 23375032
[TBL] [Abstract][Full Text] [Related]
19. Expression of the matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 in systemic lupus erythematosus patients.
Vira HJ; Pradhan VD; Umare VD; Chaudhary AK; Rajadhyksha AG; Nadkar MY; Ghosh K; Nadkarni AH
Neth J Med; 2020 Sep; 78(5):261-268. PubMed ID: 33093251
[TBL] [Abstract][Full Text] [Related]
20. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
